MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation

Recruiting now

Conditions studied: Kidney Transplant; Complications, Liver Transplant; Complications

In brief

To define the sensibility and the specificity of increased levels of MR-proADM for early, non-invasive, diagnosis of AR and DGF after kidney and liver transplantation creating a predictive model for related complications after kidney and liver transplantation based on the pre-operative and post-operative levels of MR-proADM and by a machine learning process.

Key facts

Study ID

NCT06130046

Run by

University of Rome Tor Vergata

People needed

300

Starts

2022-12-01

Expected to finish

2026-12-01

Last updated by the study team

2025-08-01

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Kidney transplant recipient at our Institution
• Liver transplant recipient at our Institution

You may not qualify if…

• Re-transplantation
• Dual kidney transplantation
• Combined transplant (kidney-liver, kidney-pancreas)
• Autoimmune disease as indication to transplant

Where it is running

• University of Rome Tor Vergata — Rome, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.